Please provide your email address to receive an email when new articles are posted on . Lefamulin demonstrated high early clinical response and was safe in patients with community-acquired bacterial ...

Lefamulin is a first-in-class, semi-synthetic pleuromutilin antibiotic Nabriva Therapeutics announced the submission of two New Drug Applications (NDAs) to the Food and Drug Administration (FDA) for ...

Previously, the initial loading dose of Nuzyra for CABP was administered only by IV infusion. An oral-only dosing regimen of Nuzyra ® (omadacycline) for the treatment of adults with community-acquired ...

CAB Payments Holdings PLC Annual stock financials by MarketWatch. View the latest CABP financial statements, income statements and financial ratios.

Increased rates of resistance of Streptococcus pneumoniae to currently available macrolides such as azithromycin and clarithromycin have increased the challenges of treating community-acquired ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued a complete response letter to Cempra Inc. stating that the company must provide additional safety ...

The Company believes that Restanza fulfills an unmet medical need in that it displays superior in vitro and in vivo efficacy against macrolide-resistant Streptococcus pneumoniae (MRSP) compared to ...

CAB Payments Holdings Limited ( (GB:CABP)) has provided an update. CAB Payments Holdings plc has announced it will release an update on its 2025 trading performance on January 15, 2026, followed by ...

FDA releases guidance on developing drugs for the treatment of community-acquired bacterial pneumonia. FDA has released Guidance for Industry, Community-Acquired Bacterial Pneumonia: Developing Drugs ...

ABSTRACT: The vitamin D-dependent calcium-binding protein (CaBP) cholecalcin or calbindin, has been used as a molecular marker of 1,25-dihydroxyvitamin D 3 action. Mammals possess two CaBPs: a 9,000 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.